Heart, Kidney Failure Mark End of the Road for BMS HCV Drug
Bristol-Myers Squibb Co. shut down development of its hepatitis C virus (HCV) drug, BMS-986094, following a fatality and nine hospitalizations in a Phase II trial of the drug. The trial was suspended on Aug. 1, and the FDA placed the compound on clinical hold. BMS and the FDA are working together to follow up on the incidents, which involve heart and lung toxicity.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST